Phage Therapy of Mycobacterium Infections: Compassionate Use of Phages in 20 Patients With Drug-Resistant Mycobacterial Disease
Clinical Infectious Diseases · 06.01.2023 · 76 (1) · 103-112
DOI: 10.1093/cid/ciac453 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Infectious Diseases, online erschienen am 09.06.2022. Verfasst von Rebekah M Dedrick und 34 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biological Sciences, University of Pittsburgh, Pittsburgh, Pennsylvania, USA. Hauptthemen laut MEDLINE: Phage Therapy, Bacteriophages, Mycobacterium, Mycobacterium Infections, Nontuberculous. Die Arbeit wurde bisher 361-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, NIGMS NIH HHS, NIAID NIH HHS.
Abstract (Originalsprache)
Background
Nontuberculous Mycobacterium infections, particularly Mycobacterium abscessus, are increasingly common among patients with cystic fibrosis and chronic bronchiectatic lung diseases. Treatment is challenging due to intrinsic antibiotic resistance. Bacteriophage therapy represents a potentially novel approach. Relatively few active lytic phages are available and there is great variation in phage susceptibilities among M. abscessus isolates, requiring personalized phage identification.
Methods
Mycobacterium isolates from 200 culture-positive patients with symptomatic disease were screened for phage susceptibilities. One or more lytic phages were identified for 55 isolates. Phages were administered intravenously, by aerosolization, or both to 20 patients on a compassionate use basis and patients were monitored for adverse reactions, clinical and microbiologic responses, the emergence of phage resistance, and phage neutralization in serum, sputum, or bronchoalveolar lavage fluid.
Results
No adverse reactions attributed to therapy were seen in any patient regardless of the pathogen, phages administered, or the route of delivery. Favorable clinical or microbiological responses were observed in 11 patients. Neutralizing antibodies were identified in serum after initiation of phage delivery intravenously in 8 patients, potentially contributing to lack of treatment response in 4 cases, but were not consistently associated with unfavorable responses in others. Eleven patients were treated with only a single phage, and no phage resistance was observed in any of these.
Conclusions
Phage treatment of Mycobacterium infections is challenging due to the limited repertoire of therapeutically useful phages, but favorable clinical outcomes in patients lacking any other treatment options support continued development of adjunctive phage therapy for some mycobacterial infections.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biological Sciences, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
- School of Women's and Children's Health, University of New South Wales, Sydney, New South Wales, Australia.
- Department of Respiratory Medicine, Sydney Children's Hospital, Sydney, New South Wales, Australia.
- Inova Fairfax Hospital, Falls Church, Virginia, USA.
- Division of Pulmonary and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
- Center for Genes, Environment, and Health, National Jewish Health, Denver, Colorado, USA.
ORCID-Profile: Graham F Hatfull
Förderung
- NHLBI NIH HHS
- NIGMS NIH HHS
- NIAID NIH HHS
- Howard Hughes Medical Institute
- Cystic Fibrosis Foundation
- National Heart, Lung, and Blood Institute
- Burroughs Wellcome Fund
- NIH
Zitieren
APA
Dedrick, R. M., Smith, B. E., Cristinziano, M., Freeman, K. G., Jacobs-Sera, D., Belessis, Y., Whitney Brown, A., Cohen, K. A., Davidson, R. M., van Duin, D., Gainey, A., Garcia, C. B., Robert George, C. R., Haidar, G., Ip, W., Iredell, J., Khatami, A., Little, J. S., Malmivaara, K., …, & Hatfull, G. F. (2023). Phage Therapy of Mycobacterium Infections: Compassionate Use of Phages in 20 Patients With Drug-Resistant Mycobacterial Disease. Clinical Infectious Diseases, 76(1), 103-112. https://doi.org/10.1093/cid/ciac453
Vancouver
Dedrick RM, Smith BE, Cristinziano M, Freeman KG, Jacobs-Sera D, Belessis Y, et al. Phage Therapy of Mycobacterium Infections: Compassionate Use of Phages in 20 Patients With Drug-Resistant Mycobacterial Disease. Clinical Infectious Diseases. 2023;76(1):103-112. doi:10.1093/cid/ciac453
BibTeX
@article{Dedrick2023,
author = {Dedrick, Rebekah M and Smith, Bailey E and Cristinziano, Madison and Freeman, Krista G and Jacobs-Sera, Deborah and Belessis, Yvonne and Whitney Brown, A and Cohen, Keira A and Davidson, Rebecca M and van Duin, David and Gainey, Andrew and Garcia, Cristina Berastegui and Robert George, C R and Haidar, Ghady and Ip, Winnie and Iredell, Jonathan and Khatami, Ameneh and Little, Jessica S and Malmivaara, Kirsi and McMullan, Brendan J and Michalik, David E and Moscatelli, Andrea and Nick, Jerry A and Tupayachi Ortiz, Maria G and Polenakovik, Hari M and Robinson, Paul D and Skurnik, Mikael and Solomon, Daniel A and Soothill, James and Spencer, Helen and Wark, Peter and Worth, Austen and Schooley, Robert T and Benson, Constance A and Hatfull, Graham F},
title = {Phage Therapy of Mycobacterium Infections: Compassionate Use of Phages in 20 Patients With Drug-Resistant Mycobacterial Disease},
journal = {Clinical Infectious Diseases},
year = {2023},
volume = {76},
number = {1},
pages = {103--112},
doi = {10.1093/cid/ciac453}
}
EUVIMED